Delta Dental of New Jersey invests in new drug to fight tooth decay

Category
New Products/Research
Press Release

PARSIPPANY, N.J. — April 07, 2014 — Delta Dental of New Jersey has invested $5 million in C3 Jian, Inc. to support the company’s development of an antimicrobial drug that targets the bacteria responsible for tooth decay. It is one of several Delta Dental member companies and affiliated organizations that have made substantial investments in C3 Jian.

C3 Jian, Inc. is a private company focused on developing proprietary drugs with a focus on improving oral healthcare. Its lead product, called C16G2, is a proprietary peptide-based antimicrobial drug specifically targeting Streptococcus mutans, a bacterium responsible for dental caries, or tooth decay. Under a U.S. FDA Investigational New Drug Application, the company recently began a Phase 2 Clinical Trial to study C16G2 formulated as a mouth rinse, as well as a gel, for both dental tray and toothbrush applications.

“Tooth decay is the most common chronic disease of childhood, yet it’s nearly 100% preventable,” said Ronald Deblinger, D.M.D., chairman, Board of Trustees, Delta Dental of New Jersey. “This new treatment has the potential to help eradicate the disease and improve the oral health, and by connection the overall health, of people everywhere.”

“We view this as an investment in exciting research that could potentially stop tooth decay,” added Dennis G. Wilson, president and CEO, Delta Dental of New Jersey. “This advances our mission to promote oral health through preventive care and quality dental services.”

About C3 Jian, Inc.
C3 Jian is a clinical-stage biotechnology company developing and commercializing novel products to diagnose, treat and prevent diseases related to the human microbiome, with an initial focus on improving oral health. C3 is advancing proprietary targeted solutions, which can offer more selective, efficacious and safer treatment modalities than broad spectrum antibiotics. The Company’s platform cell signaling STAMP technology has potential applications to a variety of diseases and disorders particularly related to bacterial and fungal infections. C3 Jian is based in Los Angeles, California. For more information about the company, please visit WWW.C3-JIAN.COM.

About Delta Dental
Delta Dental of New Jersey Inc. is New Jersey’s leading dental benefits company, providing or administering coverage to more than 1.5 million people through contracts with groups in New Jersey and Connecticut. In Connecticut, Delta Dental Insurance Company writes dental coverage on an insured basis and Delta Dental of New Jersey administers self-funded dental benefit programs. For more information, visit www.deltadentalnj.com.